By Shawn Arrajj
Fact checked by Shenaz Bagha
Published August 03, 2026
Key Takeaways:
- The drug works by inhibiting amyloid beta oligomer formation.
- Patients with MCI taking valiltramiprosate saw a 36% decrease in plasma p-tau217 after 78 weeks, compared with a 17% increase for placebo.
Valiltramiprosate, a drug in development as a disease-modifying therapy for Alzheimer’s disease, showed rapid and sustained reduction of plasma p-tau217, among other clinical benefits, according to data from the developer.
Valiltramiprosate (ALZ-801, Alzheon) is taken orally and acts as a small-molecule inhibitor of amyloid oligomer formation, according to information presented at Alzheimer’s Association International Conference 2026. The drug’s effects in mild cognitive impairment (MCI) AD subjects were correlated with cognitive testing results and vMRI measures of hippocampal volume and cortical thickness, said John Hey, PhD, chief scientific officer at Alzheon.
“The important findings with p-tau217/amyloid beta 42 is that these biomarkers now enable physicians to identify these patients earlier and therefore bring potential therapeutic options to them earlier,” Hey told Healio. “In the case of valiltramiprosate, what we’re seeing is that we’re getting these effects short term after dosing.”
The phase 3 APOLLOE4 trial examined the drug’s effects on APOE4/4 homozygotes with early Alzheimer’s disease. APOE4/4 homozygotes face the highest risk for Alzheimer’s disease, develop the disease earlier than other carriers, develop more aggressive forms and have the greatest unmet need in terms of safe and effective treatments, Hey said. APOLLOE4 was the largest phase 3 interventional trial exclusively examining APOE4/4 homozygous subjects.
